• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

    3/8/23 5:30:00 PM ET
    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Computer Software: Prepackaged Software
    Technology
    Diversified Commercial Services
    Miscellaneous
    Get the next $BBAI alert in real time by email

    Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection with the following special purpose acquisition companies ("SPACs"): BigBear.ai Holdings, Inc. f/k/a GigCapital4 Inc. (NYSE:BBAI), Senti Biosciences, Inc. f/k/a Dynamics Special Purpose Corp (NASDAQGM:SNTI), Tango Therapeutics, Inc. f/k/a BCTG Acquisition Corp (NASDAQGM:TNGX), and Boxed, Inc. f/k/a Seven Oaks Acquisition Corp (NYSE:BOXD).

    If you are an affected investor, and you want to learn more about this investigation, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, (972) 521-6868, or via email at [email protected]. There is no cost or fee to you.

    The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 23 years of experience in complex securities litigation and transactional matters.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005867/en/

    Get the next $BBAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBAI
    $BOXD
    $SNTI
    $TNGX

    CompanyDatePrice TargetRatingAnalyst
    Tango Therapeutics Inc.
    $TNGX
    11/18/2025Peer Perform
    Wolfe Research
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Tango Therapeutics Inc.
    $TNGX
    8/19/2025$11.00Overweight
    Piper Sandler
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    BigBear.ai Inc.
    $BBAI
    3/7/2025$2.50 → $4.00Outperform → Market Perform
    Northland Capital
    BigBear.ai Inc.
    $BBAI
    12/30/2024$3.00 → $7.00Buy
    H.C. Wainwright
    Tango Therapeutics Inc.
    $TNGX
    7/17/2024$19.00Buy
    Jefferies
    Tango Therapeutics Inc.
    $TNGX
    4/4/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that effective December 12, 2025 Senti Bio's Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company's common stock with a per share exercise price of $1.31 per share. These awards were made under the Company's Amended and Restated 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees enteri

    12/18/25 5:30:00 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BigBear.ai and C Speed Announce Strategic Partnership to Deliver AI-Enabled Border Security

    BigBear.ai (NYSE:BBAI), a leading provider of mission-ready AI for national security, today announced a strategic partnership with C Speed, LLC (C Speed), a U.S.-based leader in radar and defense solutions, and a NewSpring Holdings' platform company. Together, the companies will integrate BigBear.ai's ConductorOS AI orchestration platform with C Speed's software-defined LightWave Radar (LWR) system to deliver intelligent, autonomous, and real-time threat detection and decision support for global defense and homeland security partners. The collaboration focuses on integrating AI-enabled threat detection, reporting, and response solutions into C Speed's LWR suite of surveillance radars suppo

    12/18/25 4:30:00 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

    BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated

    12/17/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Ricker Sean Raymond covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.25% to 487,489 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    12/9/25 4:20:21 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Ricker Sean Raymond sold $35,296 worth of shares (5,000 units at $7.06), decreasing direct ownership by 1% to 488,716 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    12/8/25 4:55:40 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Director Hayes Dorothy D sold $133,870 worth of shares (22,000 units at $6.08), decreasing direct ownership by 9% to 236,150 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    11/19/25 7:03:52 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Tango Therapeutics

    Wolfe Research initiated coverage of Tango Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Senti Bio with a new price target

    H.C. Wainwright initiated coverage of Senti Bio with a rating of Buy and set a new price target of $12.00

    10/14/25 8:53:29 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Tango Therapeutics with a new price target

    Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $11.00

    8/19/25 8:36:26 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Mission Critical Group Appoints Julie Peffer as Chief Financial Officer

    MCKINNEY, Texas, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mission Critical Group ("MCG"), a critical power infrastructure company specializing in the design, manufacturing, delivery, and service of advanced electrical systems, today announces the appointment of Julie Peffer as Chief Financial Officer. Peffer brings more than three decades of experience leading financial operations and strategic growth initiatives across global organizations, including Amazon Web Services (AWS), Flowserve, Raytheon, Lennox International, and Textron. She joins MCG from BigBear.ai (NYSE:BBAI), where she served as CFO and guided the company's financial strategy through rapid expansion in the defense and artificial

    10/21/25 8:05:00 AM ET
    $BBAI
    $NINE
    Computer Software: Prepackaged Software
    Technology
    Oilfield Services/Equipment
    Energy

    BigBear.ai Announces CFO Transition

    BigBear.ai (NYSE:BBAI) announced today, June 6, 2025, that Sean Ricker has been appointed interim Chief Financial Officer, effective immediately, succeeding Julie Peffer as Chief Financial Officer. "I am pleased to announce the interim appointment of Sean Ricker as our Chief Financial Officer. Sean has a wealth of experience at BigBear.ai, where he most recently held the role of Chief Accounting Officer, prior to which he was Corporate Controller," said Kevin McAleenan, Chief Executive Officer. "Sean joined us shortly before BigBear.ai became a public company and has been a key leader in getting us to this stage in our growth. Given his familiarity with the business, stakeholders, and o

    6/6/25 4:44:00 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

    Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

    4/10/25 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/10/24 4:15:32 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that effective December 12, 2025 Senti Bio's Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company's common stock with a per share exercise price of $1.31 per share. These awards were made under the Company's Amended and Restated 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees enteri

    12/18/25 5:30:00 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

    RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers benefits of FDA working closely with Senti Bio to provide guidance and advice on generating the data needed to support approval of the product in an efficient mannerSecond FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety profileData released at the American Society of Hematology (ASH) Annual Meeting on December 8, 2025 showed 50% Overall Resp

    12/9/25 7:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

    ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of all responses were MRD negative) at RP2D, 7.6 months median duration of composite Complete Remission across all patients, and a favorable safety profilePharmacodynamic data from these patients validate SENTI-202's novel OR/NOT Logic Gate mechanism of action for selectively killing AML blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs) and reinforce the potential of Senti's Logic Gates in a new generation of precise and effective cell thera

    12/9/25 7:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    SEC Filings

    View All

    SEC Form DEFA14A filed by BigBear.ai Inc.

    DEFA14A - BigBear.ai Holdings, Inc. (0001836981) (Filer)

    12/16/25 4:06:55 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form EFFECT filed by Tango Therapeutics Inc.

    EFFECT - Tango Therapeutics, Inc. (0001819133) (Filer)

    12/11/25 12:15:04 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by BigBear.ai Inc.

    DEFA14A - BigBear.ai Holdings, Inc. (0001836981) (Filer)

    12/10/25 6:01:13 AM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Braden Pamela Joyce bought $209,999 worth of shares (140,939 units at $1.49), increasing direct ownership by 46% to 446,396 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    6/6/24 5:52:55 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Braden Pamela Joyce bought $96,048 worth of shares (50,025 units at $1.92), increasing direct ownership by 20% to 305,457 units (SEC Form 4)

    4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

    12/21/23 5:21:13 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology